ACTengine® IMA203 Combined With mRNA-4203 (NCT06946225)
A First-in-human, Open-label Trial to Evaluate the Combination of ACTengine® IMA203 With mRNA-4203 in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma or Synovial Sarcoma Patients (ACTengine® IMA203-102)
🩺 Plain-English Summary (8th-Grade Level)
This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).
Who can join: Review the eligibility criteria below.
Location: University of California San Francisco — San Francisco, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- University of California San Francisco — San Francisco, California
- Dana Farber Cancer Institute — Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center — New York, New York
- MD Anderson Cancer Center — Houston, Texas
📞 Contact the Study Coordinator
Phone: (346) 204-5400
Email: ctgovinquiries@immatics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cutaneous Melanoma
- Neoadjuvant Atezolizumab in Cutaneous Melanoma — Houston, Texas
- Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma — Boston, Massachusetts
- Exercise to Boost Response to Checkpoint Blockade Immunotherapy — Orlando, Florida
- Exercise to Boost Response to Checkpoint Blockade Immunotherapy — Tampa, Florida
- A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients — Pittsburgh, Pennsylvania
- Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma — San Francisco, California
Explore by condition: All Cutaneous Melanoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.